• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。

Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

作者信息

Sheiner L B, Beal S L

出版信息

J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.

DOI:10.1007/BF01060053
PMID:7229908
Abstract

Individual pharmacokinetic par parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean kinetics, interindividual variability, and residual intraindividual variability plus measurement error. Individual pharmacokinetics are estimated by fitting individual data to a pharmacokinetic model. Population pharmacokinetic parameters are estimated either by fitting all individual's data together as though there was no individual kinetic differences (the naive pooled data approach), or by fitting each individual's data separately, and then combining the individual parameter estimates (the two-stage approach). A third approach, NONMEM, takes a middle course between these, and avoids shortcomings of each of them. A data set consisting of 124 steady-state phenytoin concentration-dosage pairs from 49 patients, obtained in the routine course of their therapy, was analyzed by each method. The resulting population parameter estimates differ considerably (population mean Km, for example, is estimated as 1.57, 5.36, and 4.44 micrograms/ml by the naive pooled data, two-stage, and NONMEN approaches, respectively). Simulations of the data were analyzed to investigate these differences. The simulations indicate that the pooled data approach fails to estimate variabilities and produces imprecise estimates of mean kinetics. The two-stage approach produces good estimates of mean kinetics, but biased and imprecise estimates of interindividual variability. NONMEN produces accurate and precise estimates of all parameters, and also reasonable confidence intervals for them. This performance is exactly what is expected from theoretical considerations and provides empirical support for the use of NONMEM when estimating population pharmacokinetics from routine type patient data.

摘要

个体药代动力学参数用于量化个体的药代动力学,而群体药代动力学参数则用于量化群体平均动力学、个体间变异性以及个体内残余变异性加测量误差。个体药代动力学通过将个体数据拟合到药代动力学模型来估算。群体药代动力学参数的估算方法有两种:一种是将所有个体的数据一起拟合,就好像不存在个体动力学差异一样(即简单合并数据法);另一种是分别拟合每个个体的数据,然后合并个体参数估计值(即两阶段法)。第三种方法,即NONMEM法,介于这两种方法之间,避免了它们各自的缺点。对一组由49名患者在常规治疗过程中获得的124个稳态苯妥英浓度-剂量对组成的数据集,分别用这三种方法进行了分析。得出的群体参数估计值差异很大(例如,简单合并数据法、两阶段法和NONMEM法估计的群体平均Km分别为1.57、5.36和4.44微克/毫升)。对数据进行模拟分析以研究这些差异。模拟结果表明,合并数据法无法估计变异性,并且对平均动力学的估计不准确。两阶段法对平均动力学的估计较好,但对个体间变异性的估计有偏差且不准确。NONMEM法对所有参数都能进行准确而精确的估计,并且能给出合理的置信区间。这种性能与理论考虑完全相符,为从常规患者数据估算群体药代动力学时使用NONMEM法提供了实证支持。

相似文献

1
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
2
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
3
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.群体药代动力学参数估计方法的评估。II. 双指数模型与实验药代动力学数据
J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.
4
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.药代动力学数据分析的群体方法:原理与标准数据分析方法
Drug Metab Rev. 1984;15(1-2):153-71. doi: 10.3109/03602538409015063.
5
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.群体药代动力学参数估计的替代方法:与非线性混合效应模型的比较。
Drug Metab Rev. 1984;15(1-2):265-92. doi: 10.3109/03602538409015066.
6
Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.NONMEM的应用经验:苯妥英钠常规临床药代动力学数据分析
Drug Metab Rev. 1984;15(1-2):293-303. doi: 10.3109/03602538409015067.
7
Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model.使用平行米氏方程和一级消除模型验证苯妥英钠的群体药代动力学参数。
Ther Drug Monit. 2000 Jun;22(3):313-9. doi: 10.1097/00007691-200006000-00013.
8
Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.
J Pharm Sci. 1977 Apr;66(4):530-3. doi: 10.1002/jps.2600660417.
9
Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.苯妥英在日本癫痫患者中的群体药代动力学:采用剂量依赖性清除模型进行分析。
Biol Pharm Bull. 1996 Mar;19(3):444-8. doi: 10.1248/bpb.19.444.
10
Analytical approximations of sensitivities of steady state predictions to errors in parameter estimation: II. Michaelis-Menten kinetics.稳态预测对参数估计误差的敏感性的解析近似:II. 米氏动力学
J Pharmacokinet Biopharm. 1984 Oct;12(5):525-34. doi: 10.1007/BF01060130.

引用本文的文献

1
In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.在药代动力学方法的摇篮中:介绍群体药代动力学-药效学建模、同步分析和效应室模型——对谢纳等人的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1516-1532. doi: 10.1002/cpt.3663.
2
Population pharmacokinetic analysis of intravenous voriconazole in cancer patients.癌症患者静脉注射伏立康唑的群体药代动力学分析。
PLoS One. 2025 Mar 27;20(3):e0318883. doi: 10.1371/journal.pone.0318883. eCollection 2025.
3
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.

本文引用的文献

1
A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.苯妥英钠(二苯乙内酰脲)在癫痫患者中的药代动力学研究及用于剂量递增的列线图的制定。
Epilepsia. 1975 Nov;16(4):627-46. doi: 10.1111/j.1528-1157.1975.tb04745.x.
2
Predictability of phenytoin serum levels by nomograms and clinicians.
Eur Neurol. 1980;19(6):345-52. doi: 10.1159/000115174.
3
On the stochastic modeling of tracer kinetics.关于示踪剂动力学的随机建模
用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法:中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.
4
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.在临床实践中,将群体药代动力学建模与精准给药相结合的推荐方法。
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
5
Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors.基于生理的 OATP1B 底物的药代动力学模型:采用非线性混合效应方法估算经验性的体外到体内比例因子。
Clin Pharmacokinet. 2024 Aug;63(8):1177-1189. doi: 10.1007/s40262-024-01408-w. Epub 2024 Aug 19.
6
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations.深部房室模型中的混合效应估计:变分方法优于一阶近似。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):797-808. doi: 10.1007/s10928-024-09931-w. Epub 2024 Jul 4.
7
RPEM: Randomized Monte Carlo parametric expectation maximization algorithm.RPEM:随机蒙特卡罗参数期望最大化算法。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):759-780. doi: 10.1002/psp4.13113. Epub 2024 Apr 15.
8
Learning pharmacometric covariate model structures with symbolic regression networks.使用符号回归网络学习药代动力学协变量模型结构。
J Pharmacokinet Pharmacodyn. 2024 Apr;51(2):155-167. doi: 10.1007/s10928-023-09887-3. Epub 2023 Oct 21.
9
The Utility of Mixed Effects Models in the Evaluation of Complex Genomic Traits In Vitro.混合效应模型在体外评估复杂基因组特征中的应用。
Drug Metab Dispos. 2023 Nov;51(11):1455-1462. doi: 10.1124/dmd.123.001260. Epub 2023 Aug 10.
10
Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.多格列艾汀在健康受试者和 2 型糖尿病患者中的群体药代动力学分析。
Clin Pharmacokinet. 2023 Oct;62(10):1413-1425. doi: 10.1007/s40262-023-01286-8. Epub 2023 Aug 3.
Fed Proc. 1980 Jan;39(1):104-9.
4
Modelling of individual pharmacokinetics for computer-aided drug dosage.用于计算机辅助药物剂量计算的个体药代动力学建模。
Comput Biomed Res. 1972 Oct;5(5):411-59. doi: 10.1016/0010-4809(72)90051-1.
5
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.根据常规临床数据估算药代动力学参数的群体特征。
J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79. doi: 10.1007/BF01061728.
6
Micro-determination of plasma diphenylhydantoin by gas-liquid chromatography.气液色谱法微量测定血浆中的苯妥英
J Chromatogr. 1977 Mar 1;143(2):171-81.
7
Individualization of phenytoin dosage regimens.
Clin Pharmacol Ther. 1977 Mar;21(3):287-93. doi: 10.1002/cpt1977213287.
8
Forecasting individual pharmacokinetics.预测个体药代动力学。
Clin Pharmacol Ther. 1979 Sep;26(3):294-305. doi: 10.1002/cpt1979263294.
9
Letter: Phenytoin dosage nomogram.信函:苯妥英钠剂量图。
Lancet. 1975 Dec 27;2(7948):1305-6. doi: 10.1016/s0140-6736(75)90640-6.
10
Serum-phenytoin levels in management of epilepsy.癫痫治疗中血清苯妥英水平
Lancet. 1975 Aug 9;2(7928):247-8. doi: 10.1016/s0140-6736(75)90962-9.